PL415888A1 - Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie - Google Patents
Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobieInfo
- Publication number
- PL415888A1 PL415888A1 PL415888A PL41588816A PL415888A1 PL 415888 A1 PL415888 A1 PL 415888A1 PL 415888 A PL415888 A PL 415888A PL 41588816 A PL41588816 A PL 41588816A PL 415888 A1 PL415888 A1 PL 415888A1
- Authority
- PL
- Poland
- Prior art keywords
- derivatives
- polypeptide
- insulin
- peptide used
- seq
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 101800000120 Host translation inhibitor nsp1 Proteins 0.000 abstract 1
- 101800000517 Leader protein Proteins 0.000 abstract 1
- 101800000512 Non-structural protein 1 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108010068380 arginylarginine Proteins 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Przedmiotem zgłoszenia jest polipeptyd, posiadający sekwencję aminokwasową o wzorze ogólnym: Xn - B - Arg - Arg - A, gdzie: A oznacza polipeptyd łańcucha A insuliny lub jej analogu, korzystnie o sekwencji wybranej spośród Sekw. Nr Id.: 1 - 4, B oznacza polipeptyd łańcucha B insuliny lub jej analogu, korzystnie o sekwencji wybranej spośród Sekw. Nr Id.: 5 - 7, n oznacza 0 lub 1, X oznacza polipeptyd białka liderowego, korzystnie o sekwencji wybranej spośród SOD o Sekw. Nr Id.: 8 lub UBI o Sekw. Nr Id.: 9. Ponadto zgłoszenie obejmuje także sposób wytwarzania insuliny ludzkiej.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415888A PL239062B1 (pl) | 2016-01-22 | 2016-01-22 | Sposób wytwarzania insuliny i jej pochodnych |
| PCT/PL2017/050003 WO2017126984A1 (en) | 2016-01-22 | 2017-01-22 | A method for producing insulin and insulin derivatives, and hybrid peptide used in this method |
| EP17741726.8A EP3405484A4 (en) | 2016-01-22 | 2017-01-22 | METHOD FOR PRODUCING INSULIN AND INSULIN DERIVATIVES AND HYBRID PEPTIDE USED IN THIS PROCESS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415888A PL239062B1 (pl) | 2016-01-22 | 2016-01-22 | Sposób wytwarzania insuliny i jej pochodnych |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL415888A1 true PL415888A1 (pl) | 2017-07-31 |
| PL239062B1 PL239062B1 (pl) | 2021-11-02 |
Family
ID=59361950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL415888A PL239062B1 (pl) | 2016-01-22 | 2016-01-22 | Sposób wytwarzania insuliny i jej pochodnych |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3405484A4 (pl) |
| PL (1) | PL239062B1 (pl) |
| WO (1) | WO2017126984A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105635A (zh) * | 2018-06-18 | 2020-12-18 | 联合化学实验室有限公司 | 用于重组蛋白的更高表达的前导序列 |
| KR20210102347A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체 |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| KR20220112817A (ko) * | 2019-12-10 | 2022-08-11 | 사노피 | 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법 |
| CN113527505A (zh) * | 2020-04-15 | 2021-10-22 | 博锐生物科技有限公司 | 一种多肽和包含该多肽的药物组合物以及它们的应用 |
| CN113527506A (zh) * | 2020-04-15 | 2021-10-22 | 博锐生物科技有限公司 | 融合蛋白及其应用 |
| CN113801236A (zh) * | 2020-06-11 | 2021-12-17 | 宁波鲲鹏生物科技有限公司 | 一种赖脯胰岛素的制备方法 |
| CN113105536B (zh) * | 2020-09-11 | 2023-07-18 | 美药星（南京）制药有限公司 | 一种新甘精胰岛素原及其制备甘精胰岛素的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK129385A (da) * | 1985-03-22 | 1986-09-23 | Novo Industri As | Peptider og fremstilling deraf |
| ATE203998T1 (de) * | 1993-04-27 | 2001-08-15 | Hoechst Ag | Amorphe monosphärische formen von insulinderivaten |
| US6001604A (en) * | 1993-12-29 | 1999-12-14 | Bio-Technology General Corp. | Refolding of proinsulins without addition of reducing agents |
| BR9408638A (pt) * | 1994-12-29 | 2004-09-21 | Bio Technology General Corp | Geração de insulina humana |
| RU2495131C2 (ru) * | 2008-02-19 | 2013-10-10 | Байокон Лимитид | Способ получения рекомбинантного инсулина гларгина |
| PL219335B1 (pl) * | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| WO2014122653A1 (en) * | 2013-02-07 | 2014-08-14 | Valin Technologies Ltd. | Process for preparing insulin |
-
2016
- 2016-01-22 PL PL415888A patent/PL239062B1/pl unknown
-
2017
- 2017-01-22 EP EP17741726.8A patent/EP3405484A4/en not_active Withdrawn
- 2017-01-22 WO PCT/PL2017/050003 patent/WO2017126984A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3405484A4 (en) | 2019-11-06 |
| WO2017126984A1 (en) | 2017-07-27 |
| PL239062B1 (pl) | 2021-11-02 |
| EP3405484A1 (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie | |
| MY190623A (en) | Anti-vegf protein compositions and methods for producing the same | |
| MX2018003410A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| BR112019002848A2 (pt) | anticorpo anti-lag-3 | |
| CY1119926T1 (el) | Νεοι μεταλλακτες prongf και χρησεις αυτων στην παραγωγη bhta-ngf | |
| MX389878B (es) | Proteinas quimericas de factor viii y usos de estas. | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| EP4374913A3 (en) | Novel human serum albumin mutant | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
| BR112018013246A2 (pt) | rótulo de peptídeo e proteína rotulada incluindo o mesmo | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| MX2021001507A (es) | Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. | |
| EA202090143A1 (ru) | Фармацевтически приемлемые соли полипептидов и их применение | |
| EA201690056A1 (ru) | ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| ZA202203360B (en) | Peptide amide composition and preparation method therefor | |
| BR112021011595A2 (pt) | Proteína biespecífica | |
| MX380750B (es) | Composición farmacéutica para tratar y/o prevenir el cáncer. | |
| MX2021002013A (es) | Metodos para determinar la concentracion de proteinas o peptidos y sus usos. | |
| WO2018200814A3 (en) | Modified cyclic peptides and therapeutic use thereof | |
| EA202092963A1 (ru) | Новый белок с противовоспалительными свойствами | |
| JOP20200066B1 (ar) | طريقة لتحضير أحماض ألفا هالو ألكانويك لا تماثلية | |
| BR112018011590A2 (pt) | formulação cosmética | |
| PL419327A1 (pl) | Peptydy immunosupresyjne i ich zastosowania |